Lung Cancer Therapeutics Market to Surpass 61 Billion USD by 2032
New York, Monday, 1 September 2025.
Driven by precision medicine advancements, the U.S. lung cancer therapeutics market will grow from 9.51 billion USD in 2024 to 15.86 billion USD by 2032, revolutionizing treatment.
Expanding Market through Precision Medicine
The lung cancer therapeutics market is projected to experience substantial growth, largely driven by advancements in precision medicine and immunotherapy. This market is expected to expand from USD 32.83 billion in 2024 to USD 61.08 billion by 2032 globally [1]. In the U.S., it will grow from USD 9.51 billion in 2024 to USD 15.86 billion by 2032, reflecting a compound annual growth rate (CAGR) of 6.65% [1].
Innovative Treatments Reshaping Lung Cancer Care
The market’s expansion is fueled by the clinical adoption of immune checkpoint inhibitors and a broader use of companion diagnostics. These innovations promise improved survival rates for non-small cell lung cancer (NSCLC) patients. Furthermore, targeted therapies, which made up 56.6% of the market in 2024, continue to be at the forefront of treatment advancements [1].
Global Market Drivers
Globally, the major drivers of market growth include increased awareness, early diagnosis, and innovation in targeted therapies and immunotherapies. The prevalence of lung cancer, exacerbated by smoking, environmental pollutants, and an aging population, underlines the urgent need for advanced therapeutic solutions. Non-small cell lung cancer remains the most prevalent form, seeing significant advancements in treatment due to these targeted therapies [2].
Economic Impact and Future Outlook
This predicted growth signifies a transformative effect on the healthcare economy, particularly in regions like North America and emerging markets in Asia-Pacific, which are expected to experience rapid expansion due to rising patient populations. The increased market size underscores the potential for economic opportunities within the healthcare sector, as the development of targeted therapies and immunotherapies continue to evolve [3].